These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [Abstract] [Full Text] [Related]
36. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. Sasaki A, Kawano K, Inomata M, Shibata K, Matsumoto T, Kitano S. Hepatogastroenterology; 2005 Mar; 52(66):1814-9. PubMed ID: 16334783 [Abstract] [Full Text] [Related]
37. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, Pour PM. Am J Surg Pathol; 1989 Mar; 13 Suppl 1():89-95. PubMed ID: 2699170 [Abstract] [Full Text] [Related]
39. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer. Gebauer G, Müller-Ruchholtz W. Cancer Detect Prev; 2001 Mar; 25(4):344-51. PubMed ID: 11531011 [Abstract] [Full Text] [Related]
40. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma. Shibata K, Iwaki K, Kai S, Ohta M, Kitano S. Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]